Results 41 to 50 of about 5,708 (209)

Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age [PDF]

, 2014
Background: Vaccines against pandemic A/H1N1 influenza should provide protective immunity in children, because they are at greater risk of disease than adults.
Abarca, Katia, Arora, Ashwani, Della Cioppa, Giovanni, Kieninger-Baum, Dorothee, Knuf, Markus, Lattanzi, Maria, Leroux-Roels, Geert, Pedotti, Paola, Rivera, Luis, Rümke, Hans C   +9 more
core   +2 more sources

Humoral Response to the Influenza A H1N1/09 Monovalent AS03-Adjuvanted Vaccine in Immunocompromised Patients [PDF]

Clinical Infectious Diseases, 2010
Few data are available regarding the immunogenicity and safety of the pandemic influenza vaccine in immunocompromised patients. We evaluated the humoral response to the influenza A H1N1/09 vaccine in solid-organ transplant (SOT) recipients, in patients with human immunodeficiency virus (HIV) infection, and in healthy individuals.Patients scheduled to ...
Manuel Oriol, Pascual Manuel, Hoschler Katja, Giulieri Stefano, Alves Deolinda, Ellefsen Kim, Bart Pierre-Alexandre, Venetz Jean-Pierre, Calandra Thierry, Cavassini Matthias   +9 more
openaire   +4 more sources

Low hemagglutinin antigen dose influenza vaccines adjuvanted with AS03 alter the long-term immune responses in BALB/c mice

Human Vaccines & Immunotherapeutics, 2017
We investigated the long-term immune profiles of dose-sparing, AS03-adjuvanted vaccines compared to a traditional high-dose, unadjuvated influenza vaccine formulation.
Karen K. Yam, Angela Brewer, Virginie Bleau, Édith Beaulieu, Corey P. Mallett, Brian J. Ward   +5 more
doaj   +1 more source

Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine

Expert Review of Vaccines, 2010
The first cases of pandemic influenza A (H1N1) 2009 infection were seen in Mexico in March 2009. Since then, it is thought to have been responsible for at least 18,337 deaths globally. Owing to the young age of fatalities, there have been an estimated 2 million years of life lost, which is comparable to the previous pandemics of 1957 and 1968.
Walker, Woolf T., Faust, Saul N.
openaire   +3 more sources

Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant [PDF]

Clinical and Vaccine Immunology, 2016
ABSTRACT The adjuvant AS03 is stockpiled for future formulations with new and existing vaccines for the control of pandemic influenza virus. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination.
Wilbur H, Chen, Lisa A, Jackson, Kathryn M, Edwards, Wendy A, Keitel, Heather, Hill, Diana L, Noah, C Buddy, Creech, Shital M, Patel, Brian, Mangal, Karen L, Kotloff   +9 more
openaire   +2 more sources

Adjuvanted influenza vaccines

Human Vaccines & Immunotherapeutics, 2018
In spite of current influenza vaccines being immunogenic, evolution of the influenza virus can reduce efficacy and so influenza remains a major threat to public health.
John S. Tregoning, Ryan F. Russell, Ekaterina Kinnear   +2 more
doaj   +1 more source

Asymptotic properties of free monoid morphisms [PDF]

, 2016
Motivated by applications in the theory of numeration systems and recognizable sets of integers, this paper deals with morphic words when erasing morphisms are taken into account. Cobham showed that if an infinite word $w =g(f^\omega(a))$ is the image of
Charlier, Emilie, Leroy, Julien, Rigo, Michel   +2 more
core   +1 more source

Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: randomised, active-controlled, observer-blinded, phase 3 trial

medRxiv, 2023
Background: GBP510 vaccine contains self-assembling, recombinant nanoparticles displaying SARS-CoV-2 spike receptor-binding domains. We report interim phase 3 immunogenicity results for GBP510 adjuvanted with AS03 (GBP510/AS03) compared with ChAdOx1-S ...
J. Y. Song, W. Choi, E. Kim, J. Heo, J. S. Lee, D. Jung, S. Kim, K.-H. Park, J. Eom, S. Jeong, J. Lee, K. Kwon, H. J. Choi, J. Sohn, Y. Kim, B. W. Yoo, I. Jang, P. Wysocki, F. Roman, T. Breuer, H. Kim, J. Ryu, Y. W. Park, S. -. Lee, S. Sahastrabuddhe, M. Song, N. D'Cor, L. Carter, M. R. Capeding, A. Philippot, F. Solmi, M. Ceregido, H. Park, Y. Y. Lee, P. Thaisrivichai, S. D’Souza, S. Seo, Byoung-Shik Shim, J. Carlos, E. Alberto, S. Nitayaphan, W. Ratanasuwan, P. Mootsikapun, R. Chaiwarit, L. Quang, O. Karpenko   +45 more
semanticscholar   +1 more source

Short and Long-Term Safety of the 2009 AS03-Adjuvanted Pandemic Vaccine

PLoS ONE, 2012
Background: This study assessed the short and the long term safety of the 2009 AS03 adjuvanted monovalent pandemic vaccine through an active web-based electronic surveillance. We compared its safety profile to that of the seasonal trivalent inactivated influenza vaccine (TIV) for 2010–2011.
De Serres, Gaston, Gariépy, Marie-Claude, Coleman, Brenda, Rouleau, Isabelle, McNeil, Shelly, Benoît, Mélanie, McGeer, Allison, Ambrose, Ardith, Needham, Judy, Bergeron, Chantal, Grenier, Cynthia, Sleigh, Kenna Marie, Kallos, Arlene, Ouakki, Manale, Ouhoummane, Najwa, Stiver, Grant, Valiquette, Louis, McCarthy, Anne, Bettinger, Julie A., PHAC-CIHR influenza Research Network (PCIRN)   +19 more
openaire   +5 more sources

Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older [PDF]

, 2014
BACKGROUND: The effectiveness of trivalent influenza vaccines may be reduced in older versus younger adults because of age-related immunosenescence. The use of an adjuvant in such a vaccine is one strategy that may combat immunosenescence, potentially by
A Kelso, AM Harandi, AR Falsey, B Weinberger, Béatrice Laupèze, Carine Claeys, Caroline Hervé, CG Della, Concepción Núñez López, Covadonga Caso, DM Murasko, DT O’Hagan, DW Scheifele, F Roman, F Roman, G Galli, GK Pedersen, HC Rümke, HT Maecker, I Leroux-Roels, I Mbawuike, Innocent Nnadi Mbawuike, JE McElhaney, JE McElhaney, JE McElhaney, JE McElhaney, JE McElhaney, JE McElhaney, José M Bayas, JP Hsu, JS Lefebvre, JY Song, K Goodwin, K Levie, KK McKinstry, Lidia Oostvogels, LT Reed, M Ferguson, MD Co, Mohamed El Idrissi, N Garçon, N Hehme, NW Hehme, O Boyman, P Moris, P Sfriso, Philippe Moris, Robert B Couch, S Heijmans, S Morel, S Sridhar, SE Bentebibel, SL Waldrop, T Vesikari, TM Wilkinson, TW Clark, WA Keitel, X Zhou, Y Deng, YD Mahnke   +59 more
core   +1 more source